Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apremilast
Drug ID BADD_D00156
Description Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.[A181216]
Indications and Usage Investigated for use/treatment in psoriasis and psoriatic disorders.
Marketing Status Prescription
ATC Code L04AA32
DrugBank ID DB05676
KEGG ID D08860
MeSH ID C505730
PubChem ID 10151715
TTD Drug ID D07ESC
NDC Product Code 65977-0119; 60219-1410; 60219-1744; 66406-0240; 66039-934; 70518-3155; 12658-0581; 69766-024; 59572-630; 65372-1204; 59572-631; 55513-369; 58032-2030; 59572-632; 53747-077; 55513-137; 59651-150; 53069-1040; 69766-010; 55513-485; 47621-306; 11722-062; 66406-0241; 46708-902; 65129-1383; 55111-993; 53069-1050; 73309-043; 49187-0757; 66406-0242
Synonyms apremilast | Otezla | CC 10004 | CC10004 | CC-10004
Chemical Information
Molecular Formula C22H24N2O7S
CAS Registry Number 253168-86-4
SMILES CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folliculitis23.09.04.007; 11.01.12.0180.005211%
Food allergy10.01.01.0120.005211%Not Available
Food poisoning12.03.01.024; 11.07.02.001; 07.11.01.0070.010422%Not Available
Foot fracture12.04.01.012; 15.08.03.0120.015054%Not Available
Formication19.10.02.010; 17.02.06.018--Not Available
Fracture15.08.02.001; 12.04.02.001--
Frequent bowel movements07.02.04.0020.215385%Not Available
Fungal infection11.03.05.001--Not Available
Fungal skin infection11.03.05.002; 23.09.02.0010.003474%Not Available
Furuncle23.09.01.004; 11.02.05.0080.008685%Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gallbladder disorder09.03.02.0010.031266%Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastric cancer16.13.03.001; 07.21.02.001--Not Available
Gastric haemorrhage24.07.02.007; 07.12.01.001--
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastritis erosive07.04.03.003--Not Available
Gastrooesophageal reflux disease07.02.02.0030.138379%
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastroenteritis salmonella11.02.19.003; 07.19.03.0090.001158%Not Available
Gastroenteritis viral11.05.04.005; 07.19.03.0050.041687%Not Available
Gastrointestinal carcinoma16.13.04.001; 07.21.03.001--Not Available
Gastrointestinal disorder07.11.01.0010.298760%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal infection11.01.07.012; 07.19.02.0050.005790%Not Available
Gastrointestinal pain07.01.05.0050.023739%
Generalised oedema14.05.06.007; 08.01.07.004--
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 40 Pages